Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Celltrion (068270) Reports Q1 2025 Separate Operating Profit of KRW 136.4B, Up +373.94% YoY

Posted on May 9, 2025July 15, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Reports Q1 2025 Separate Operating Profit of KRW 136.4B, Up +373.94% YoY

Source Fact: Financial Supervisory Service DART / 2025-05-09

Disclosure Type: Earnings Release (Preliminary Results) – Separate basis

💡 3-Second Summary

Celltrion’s separate operating profit for Q1 2025 increased by 373.94% year-on-year to KRW 136.4 billion, while separate revenue slightly decreased by 0.66% year-on-year to KRW 634.0 billion.

📊 1. [Key Disclosure Details and Major Figures Summary]

  • Q1 2025 Separate Performance Summary (Unit: KRW million):
    • Revenue (Sales): KRW 634,007 million (approx. KRW 634.0B)
      • Compared to previous quarter (Q4 2024): Decreased by 40.07%
      • Compared to same period last year (Q1 2024): Decreased by 0.66%
    • Operating Profit: KRW 136,423 million (approx. KRW 136.4B)
      • Compared to previous quarter (Q4 2024): Decreased by 66.52%
      • Compared to same period last year (Q1 2024): Increased by 373.94%
    • Income Before Income Taxes: KRW 203,022 million (approx. KRW 203.0B)
      • Compared to previous quarter (Q4 2024): Decreased by 58.19%
      • Compared to same period last year (Q1 2024): Increased by 311.58%
    • Net Income: KRW 166,572 million (approx. KRW 166.6B)
      • Compared to previous quarter (Q4 2024): Decreased by 56.00%
      • Compared to same period last year (Q1 2024): Increased by 173.37%
  • Reason for Changes: The disclosure did not specify the exact reasons for the changes in preliminary earnings.
  • Note: The above financial data represents separate, unaudited preliminary results based on internal accounting and is subject to change depending on the final external audit.

📈 2. [Expert View: What This Disclosure Means for Investors]

  • Year-on-Year Profitability Changes: While separate revenue remained relatively flat with a minor year-on-year decrease of 0.66%, the separate operating profit showed an increase of 373.94%. Although the official filing does not provide specific reasons for this divergence, the figures indicate a year-on-year expansion in profit margins, the exact drivers of which should be verified in subsequent full financial disclosures.
  • Significant Decline Compared to the Previous Quarter: Compared to the fourth quarter of 2024, all reported metrics, including revenue (-40.07%) and operating profit (-66.52%), showed substantial declines. Since the preliminary disclosure does not outline the causes behind these quarter-on-quarter changes, investors should note the scale of these fluctuations and track the continuity of upcoming performance data.
  • Potential Variance Due to Unaudited Status: The numbers presented in this disclosure are preliminary figures drawn from internal calculations before the conclusion of the external audit. Consequently, discrepancies may arise between these preliminary figures and the finalized audited accounts, meaning that confirming the final values remains a key step for market participants.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion’s preliminary separate financial results for the first quarter of 2025 present contrasting trends: an increase in profitability indicators such as operating profit on a year-on-year basis, alongside a double-digit decline in both revenue and profit compared to the previous quarter. As this specific regulatory filing does not include detailed explanations for these earnings fluctuations, the analysis must stay strictly confined to the directional movements of the reported figures.

For global investors, the primary checkpoints going forward will be the upcoming finalized financial statements and the accompanying detailed metrics. Verifying whether any adjustments occur during the external audit process is the first priority. Furthermore, tracking how the company formally explains the factors behind the year-on-year profit growth and the quarter-on-quarter revenue contraction in future official IR materials or periodic reports will be essential for an accurate evaluation.

📢 Disclaimer & Source Information

Source: This content was structured and newly written based on official disclosure data from the Financial Supervisory Service (DART).

Investment Risk Advisory: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion (068270) Reports Q1 2025 Consolidated Operating Profit of KRW 149.4B, Up +867.94% YoY
Next Post: [Disclosure] ISU PETASYS (007660) to Reveal Q1 2025 Earnings; Confirms Conference Call Line for Retail Shareholders

Related Posts

[Disclosure] Hanwha Aerospace (012450) Amends Record Date for New Share Allocation to May 23, 2025, Following Revised Capital Increase Timeline Disclosures
[Disclosure] Celltrion (068270) Submits Application to U.S. FDA to Amend Phase 3 Clinical Trial Plan for Cosentyx Biosimilar ‘CT-P55’ Disclosures
[Disclosure] Samsung Biologics (207940) Signs Mega CMO Contract Worth KRW 1.11T with European Pharmaceutical Company Disclosures
[Disclosure] Hanwha Ocean (042660) Announces Temporary Production Suspension and Scheduled Resumption Date at Geoje Shipyard (Accounting for 96.8% of Revenue) Disclosures
[Disclosure] SAMSUNG BIOLOGICS(207940) Reports Full-Year 2024 Consolidated Revenue Surpassing KRW 4.55T, Up 23.08% YoY Disclosures
[Disclosure] Hanwha Ocean (042660) Announces Pre-notice of Financial Results with Q1 2025 Earnings Release Scheduled for April 28 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme